
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAVenture fund
Thrive Capital was founded in 2009 by Joshua Kushner, who also cofounded the health insurer Oscar Health, and it has grown from a $10 million first fund to funds of several billion dollars. It keeps a low public profile, and its website carries little more than its name. Health deals covered by HTS include its joint lead, with DST Global, of OpenEvidence's $250 million Series D for AI medical search, and its lead of Isomorphic Labs' $2.1 billion Series B, the AI drug discovery company started by Demis Hassabis, with Alphabet and GV also investing.
Thrive Capital is a New York venture firm that invests in internet, software, and technology companies at both early and late stages.
How Thrive Capital got here, step by step.
2009
Joshua Kushner starts Thrive Capital in New York.

Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBAKeep exploring